These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 26397135

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X, Wu Y, Liu A, Tang X.
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
    Ming J, Ruan S, Wang M, Ye D, Fan N, Meng Q, Tian B, Huang T.
    Oncotarget; 2015 Dec 01; 6(38):40692-703. PubMed ID: 26517687
    [Abstract] [Full Text] [Related]

  • 6. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.
    FEBS J; 2013 Nov 01; 280(21):5237-57. PubMed ID: 23876235
    [Abstract] [Full Text] [Related]

  • 7. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS, Li Y, Zhang H, Zhang D, Zhang XB, Wang X, Yu Y.
    Theranostics; 2020 Nov 01; 10(23):10729-10742. PubMed ID: 32929377
    [Abstract] [Full Text] [Related]

  • 8. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
    Louie MC, McClellan A, Siewit C, Kawabata L.
    Mol Cancer Res; 2010 Mar 01; 8(3):343-52. PubMed ID: 20215421
    [Abstract] [Full Text] [Related]

  • 9. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J, Lu M, Jin J, Lu X, Xu T, Jin S.
    Cell Physiol Biochem; 2018 Mar 01; 50(1):136-149. PubMed ID: 30278449
    [Abstract] [Full Text] [Related]

  • 10. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C, Sukumar S.
    Cancer Res; 2013 Sep 01; 73(17):5449-58. PubMed ID: 23832664
    [Abstract] [Full Text] [Related]

  • 11. miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer.
    Chen B, Tang H, Liu X, Liu P, Yang L, Xie X, Ye F, Song C, Xie X, Wei W.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):410-7. PubMed ID: 25304371
    [Abstract] [Full Text] [Related]

  • 12. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
    Han X, Li Q, Liu C, Wang C, Li Y.
    J Cell Biochem; 2019 Aug 28; 120(8):12966-12976. PubMed ID: 31001849
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
    Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE.
    Mol Cancer; 2010 Dec 20; 9():317. PubMed ID: 21172025
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M, Ding K, Zhang G, Yin M, Yao G, Tian H, Lian J, Liu L, Liang M, Zhu T, Sun F.
    Sci Rep; 2015 Mar 04; 5():8735. PubMed ID: 25736597
    [Abstract] [Full Text] [Related]

  • 16. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
    Phuong NT, Kim SK, Im JH, Yang JW, Choi MC, Lim SC, Lee KY, Kim YM, Yoon JH, Kang KW.
    Oncotarget; 2016 Mar 22; 7(12):13902-16. PubMed ID: 26418898
    [Abstract] [Full Text] [Related]

  • 17. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA.
    Breast Cancer Res; 2015 Jan 30; 17(1):13. PubMed ID: 25633049
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.
    Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE.
    Carcinogenesis; 2010 Dec 30; 31(12):2049-57. PubMed ID: 20876285
    [Abstract] [Full Text] [Related]

  • 19. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X, Zhang B, Zhang P, Lian L, Li L, Qiu Z, Qian K, Chen A, Liu Q, Jiang Y, Cui J, Qi B.
    PLoS One; 2019 Dec 30; 14(5):e0217181. PubMed ID: 31120927
    [Abstract] [Full Text] [Related]

  • 20. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S.
    Cancer Discov; 2015 Sep 30; 5(9):944-59. PubMed ID: 26180042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.